Join
Live feed
·
PRReleasevia Quantisnow
PepGen Inc. logo

PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

ByQuantisnow·Wall Street's wire, on your screen.
PEPG· PepGen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PEPG (PepGen Inc.) and more on Quantisnow.